StreetInsider.com News Articles

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Thu, 23 Jul 2026 09:00:00 -0400

First global approval of a once-daily, orally administered, Complement Factor B inhibitor
Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH
Ciprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under review
Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring continuous life-long treatment

Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc.

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Thu, 23 Jul 2026 09:00:00 -0400

First global approval of a once-daily, orally administered, Complement Factor B inhibitor
Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH
Ciprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under review
Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring continuous life-long treatment

Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc.

China approves Nuvectis drug ciprocopan for PNH treatment

Thu, 23 Jul 2026 07:30:32 -0400

Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from China's National Medicinal Products Administration (NMPA) for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously been treated with complement inhibitors.

The approval was based on a Phase 3 head-to-head study comparing ciprocopan against Soliris (eculizumab) in treatment-naive PNH patients. The study met all primary and secondary endpoints. In the trial, 59.5% of ciprocopan-treated patients reached a hemoglobin target of 12 g/dL, compared with 8.3% in the eculizumab group. Hemoglobin increased from baseline by approximately 5.0 g/dL

China approves Nuvectis drug ciprocopan for PNH treatment

Thu, 23 Jul 2026 07:30:32 -0400

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Thu, 23 Jul 2026 07:30:00 -0400

First global approval of a once-daily, orally administered, Complement Factor B inhibitor
Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH
Ciprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under review
Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring continuous life-long treatment

Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc.

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Thu, 23 Jul 2026 07:30:00 -0400

First global approval of a once-daily, orally administered, Complement Factor B inhibitor
Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH
Ciprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under review
Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring continuous life-long treatment

Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc.

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Tue, 14 Jul 2026 10:40:00 -0400

New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharmaceutical Group. Report highlights:

Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with oncology asset NXP200, from Haisco Pharmaceutical Group. The deal, transforms Nuvectis overnight from a single mid-stage oncology story into a rare-disease player with a late-stage asset already entering regulatory review.
What makes this notable is the Phase 3 data supporting NXP100. In a

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Tue, 14 Jul 2026 10:40:00 -0400

Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with oncology asset NXP200, from Haisco Pharmaceutical Group. The deal, transforms Nuvectis overnight from a single mid-stage oncology story into a rare-disease player with a late-stage asset already entering regulatory review.
What makes this notable is the Phase 3 data supporting NXP100. In a

Form 4 Nuvectis Pharma, Inc. For: Jun 30 Filed by: Mosseri Marlio Charles

Wed, 01 Jul 2026 13:42:00 -0400

si-local-file:///var/storage/secattach/20260701/26719593.html

Form 4 Nuvectis Pharma, Inc. For: Jun 30 Filed by: Mosseri Marlio Charles

Wed, 01 Jul 2026 13:42:00 -0400

si-local-file:///var/storage/secattach/20260701/26719593.html

Form 4 Nuvectis Pharma, Inc. For: Jun 30 Filed by: BENTSUR RON

Wed, 01 Jul 2026 13:40:00 -0400

si-local-file:///var/storage/secattach/20260701/26719581.html

Form 4 Nuvectis Pharma, Inc. For: Jun 30 Filed by: BENTSUR RON

Wed, 01 Jul 2026 13:40:00 -0400

si-local-file:///var/storage/secattach/20260701/26719581.html

Form 8-K Nuvectis Pharma, Inc. For: Jun 29

Tue, 30 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260630/26714359.html

Form 8-K Nuvectis Pharma, Inc. For: Jun 29

Tue, 30 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260630/26714359.html

Form 424B5 Nuvectis Pharma, Inc.

Tue, 30 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260630/26714343.html

Form 424B5 Nuvectis Pharma, Inc.

Tue, 30 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260630/26714343.html

Nuvectis Pharma prices $100M public offering at $20 per share

Mon, 29 Jun 2026 22:30:15 -0400

Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced a public offering of 5,000,000 shares of common stock at $20.00 per share, with expected gross proceeds of $100 million, according to a press release from the clinical-stage biopharmaceutical company.

The company has also granted underwriters a 30-day option to purchase up to 750,000 additional shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to customary closing conditions.